Ruxolitinib cream + Vehicle

Phase 2Completed
0 watching 0 views this week Active
49
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hand Eczema

Conditions

Hand Eczema

Trial Timeline

Jul 31, 2023 → Dec 13, 2024

About Ruxolitinib cream + Vehicle

Ruxolitinib cream + Vehicle is a phase 2 stage product being developed by Incyte for Hand Eczema. The current trial status is completed. This product is registered under clinical trial identifier NCT05906628. Target conditions include Hand Eczema.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (6)

NCT IDPhaseStatus
NCT05906628Phase 2Completed
NCT05219864Phase 3Withdrawn
NCT05233410Phase 3Withdrawn
NCT05127421Phase 2Completed
NCT04057573Phase 3Completed
NCT04052425Phase 3Completed

Competing Products

17 competing products in Hand Eczema

See all competitors
ProductCompanyStageHype Score
Lebrikizumab + PlaceboEli LillyPhase 3
77
Methylprednisolone TabletJohnson & JohnsonPhase 2/3
65
ABT-981 + Placebo for ABT-981AbbViePhase 2
52
Pimecrolimus Cream 1%NovartisPhase 3
77
tocilizumab + saline solutionRochePhase 3
77
denosumab + PlaceboAmgenPhase 2
51
Dupilumab + PlaceboSanofiPhase 2
51
dupilumab + PlaceboSanofiPhase 3
76
clobetasol propionateGSK plcApproved
84
urea 40% cream + fluocinonide 0.05% cream + tazarotene 0.1% cream + bland emollient cream (Udderly smooth® Udder Cream)BayerPhase 2
49
Ruxolitinib cream + VehicleIncytePhase 3
74
RuxolitinibIncytePhase 1/2
38
Ruxolitinib cream + VehicleIncytePhase 3
74
ARQ-252 cream 0.3% + ARQ-252 cream 0.1% + ARQ-252 Vehicle CreamArcutis BiotherapeuticsPhase 1/2
36
alitretinoinBasilea PharmaceuticaPhase 3
72
alitretinoinBasilea PharmaceuticaPhase 3
72
alitretinoinBasilea PharmaceuticaPhase 3
72